251 related articles for article (PubMed ID: 31570881)
1. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL; Hoes LR; van der Wijngaart H; van Berge Henegouwen JM; van Werkhoven E; Roepman P; Schilsky RL; de Leng WWJ; Huitema ADR; Nuijen B; Nederlof PM; van Herpen CML; de Groot DJA; Devriese LA; Hoeben A; de Jonge MJA; Chalabi M; Smit EF; de Langen AJ; Mehra N; Labots M; Kapiteijn E; Sleijfer S; Cuppen E; Verheul HMW; Gelderblom H; Voest EE
Nature; 2019 Oct; 574(7776):127-131. PubMed ID: 31570881
[TBL] [Abstract][Full Text] [Related]
2. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).
Haj Mohammad SF; Timmer HJL; Zeverijn LJ; Geurts BS; Spiekman IAC; Verkerk K; Verbeek FAJ; Verheul HMW; Voest EE; Gelderblom H
Acta Oncol; 2024 May; 63():368-372. PubMed ID: 38779868
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
4. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; Zeverijn LJ; van der Velden DL; van de Haar J; Roepman P; de Leng WJ; Jansen AML; van Werkhoven E; van der Noort V; Huitema ADR; Gort EH; de Groot JWB; Kerver ED; de Groot DJ; Erdkamp F; Beerepoot LV; Hendriks MP; Smit EF; van der Graaf WTA; van Herpen CML; Labots M; Hoeben A; Morreau H; Lolkema MP; Cuppen E; Gelderblom H; Verheul HMW; Voest EE
Clin Cancer Res; 2022 Apr; 28(7):1402-1411. PubMed ID: 35046062
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
[TBL] [Abstract][Full Text] [Related]
6. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
Wang S; Huang HY; Wu D; Fang H; Ying J; Bai Y; Yu Y; Fang Y; Jiang N; Sun C; Yu A; Fan Q; Xing S; Ni Y; Zhang W; Wu C; Ji X; Wang H; Guo Y; Tang Q; Wang Y; Tang Y; Li N
BMJ Open; 2021 Jun; 11(6):e044543. PubMed ID: 34083331
[TBL] [Abstract][Full Text] [Related]
7. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
[TBL] [Abstract][Full Text] [Related]
8. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J; Chen EY; Prasad V
JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
[TBL] [Abstract][Full Text] [Related]
9. The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice.
Martens UM; Schröder J; Bengsch F; Sellmann L; Busies S; Frank-Gleich S; Zaiss M; Decker T; Schneeweiss A; Schuler M; Grebhardt S; Zacharias S; Marschner N; Kasenda B; Potthoff K; Vannier C
BMC Cancer; 2023 Jun; 23(1):543. PubMed ID: 37312086
[TBL] [Abstract][Full Text] [Related]
10. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å; Russnes HG; Fagereng GL; Al-Shibli K; Andersson Y; Berg T; Bjørge L; Blix E; Bjerkehagen B; Brabrand S; Cameron MG; Dalhaug A; Dietzel D; Dønnem T; Enerly E; Flobak Å; Fluge S; Gilje B; Gjertsen BT; Grønberg BH; Grønås K; Guren T; Hamre H; Haug Å; Heinrich D; Hjortland GO; Hovig E; Hovland R; Iversen AC; Janssen E; Kyte JA; von der Lippe Gythfeldt H; Lothe R; Lund JÅ; Meza-Zepeda L; Munthe-Kaas MC; Nguyen OTD; Niehusmann P; Nilsen H; Puco K; Ree AH; Riste TB; Semb K; Steinskog ESS; Stensvold A; Suhrke P; Tennøe Ø; Tjønnfjord GE; Vassbotn LJ; Aas E; Aasebø K; Tasken K; Smeland S
J Transl Med; 2022 May; 20(1):225. PubMed ID: 35568909
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
12. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
[TBL] [Abstract][Full Text] [Related]
13. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
[TBL] [Abstract][Full Text] [Related]
14. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.
Mottini C; Napolitano F; Li Z; Gao X; Cardone L
Semin Cancer Biol; 2021 Jan; 68():59-74. PubMed ID: 31562957
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
[TBL] [Abstract][Full Text] [Related]
16. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Puco K; Fagereng GL; Brabrand S; Niehusmann P; Støre Blix E; Samdal Steinskog ES; Haug Å; Fredvik Torkildsen C; Oppedal IA; Meltzer S; Flobak Å; Johansson KAM; Bjørge L; Hjortland GO; Dalhaug A; Lund JÅ; Gilje B; Grønlie Cameron M; Hovland R; Falk RS; Smeland S; Giercksky Russnes HE; Taskén K; Helland Å; ;
Acta Oncol; 2024 May; 63():379-384. PubMed ID: 38779911
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
18. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.
Rubio-Perez C; Tamborero D; Schroeder MP; Antolín AA; Deu-Pons J; Perez-Llamas C; Mestres J; Gonzalez-Perez A; Lopez-Bigas N
Cancer Cell; 2015 Mar; 27(3):382-96. PubMed ID: 25759023
[TBL] [Abstract][Full Text] [Related]
19. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
20. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
